The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index; 23 of the 63 sources its claims cite were checked for support.
Parkin overexpression protects from ageing‐related loss of muscle mass and strength
Open accessAbstract
Key points: Recent evidence suggests that impaired mitophagy, a process in charge of removing damaged/dysfunctional mitochondria and in part regulated by Parkin, could contribute to the ageing‐related loss of muscle mass and function. In the present study, we show that Parkin overexpression attenuates ageing‐related loss of muscle mass and strength and unexpectedly causes hypertrophy in adult skeletal muscles. We also show that Parkin overexpression leads to increases in mitochondrial content and enzymatic activities. Finally, our results show that Parkin overexpression protects from ageing‐related increases in markers of oxidative stress, fibrosis and apoptosis. Our findings place Parkin as a potential therapeutic target to attenuate sarcopenia and improve skeletal muscle health and performance. The ageing‐related loss of muscle mass and strength, a process called sarcopenia, is one of the most deleterious hallmarks of ageing. Solid experimental evidence indicates that mitochondrial dysfunctions accumulate with ageing and are critical in the sarcopenic process. Recent findings suggest that mitophagy, the process in charge of the removal of damaged/dysfunctional mitochondria, is altered in aged muscle. Impaired mitophagy represents an attractive mechanism that could contribute to the accumulation of mitochondrial dysfunctions and sarcopenia. To test this hypothesis, we investigated the impact of Parkin overexpression in skeletal muscles of young and old mice. Parkin was overexpressed for 4 months in muscles of young (3 months) and late middle‐aged (18 months) mice using i.m. injections of adeno‐associated viruses. We show that Parkin overexpression increased muscle mass, fibre size and mitochondrial enzyme activities in both young and old muscles. In old mice, Parkin overexpression increased muscle strength, primordial germ cell‐1α content and mitochondrial density. Parkin overexpression also attenuated the ageing‐related increase in 4‐hydroxynonenal content (a marker of oxidative stress) and type I collagen content (a marker of fibrosis), as well as the number of terminal deoxynucleotidyl transferase dUTP nick‐end labelling‐positive myonuclei (a marker of apoptosis). Overall, our results indicate that Parkin overexpression attenuates sarcopenia and unexpectedly causes hypertrophy in adult muscles. They also show that Parkin overexpression leads to increases in mitochondrial content and enzymatic activities. Finally, our results show that Parkin overexpression protects against oxidative stress, fibrosis and apoptosis. These findings highlight that Parkin may be an attractive therapeutic target with respect to attenuating sarcopenia and improving skeletal muscle health and performance.
Overview
CoChat Summary
TL;DR
Parkin overexpression for 4 months in skeletal muscles of young and late middle-aged mice increased muscle mass, fibre size, and mitochondrial enzyme activities, and in old mice improved strength while reducing markers of oxidative stress, fibrosis, and apoptosis. These findings suggest Parkin as a potential therapeutic target to attenuate sarcopenia and improve skeletal muscle health.
Key findings
- In old mice, Parkin overexpression attenuated ageing-related loss of muscle mass and strength; in situ TA force generation was significantly increased at any given stimulation frequency compared with GFP overexpression.
- Parkin overexpression increased SDH and COX activities and, in old muscle, increased mitochondrial density by 72% compared with GFP overexpression, while decreasing the average area of individual mitochondria; PGC-1α increased in old but not young skeletal muscles.
- Parkin overexpression reduced ageing-related increases in 4-HNE content (oxidative stress marker), type I collagen content (fibrosis marker), and TUNEL-positive myonuclei (apoptosis marker) in old skeletal muscle.
- In young mice, Parkin overexpression caused hypertrophy and increased S6 protein phosphorylation (an mTORC1 activation index), but this increase was not seen in old muscle; endogenous Parkin protein content was significantly lower in old versus young TA.
Methods
- Male C57BL/6J mice received i.m. injections of AAV serotype 1 containing a muscle creatine kinase promoter driving Parkin plus GFP into the right tibialis anterior and gastrocnemius; the contralateral leg received GFP-only control AAV. Two injections separated by 2 months were used, with overexpression from 3 to 7 months (young) and 18 to 22 months (old), for a total of 4 months.
- Outcomes included in situ TA contractile function, histology/immunostaining for fibre size, SDH and COX activities, PGC-1α, type I collagen, 4-HNE, and TUNEL; immunoblotting; transmission electron microscopy; and quantitative real-time PCR.
- Statistical analyses used bilateral unpaired t tests, two-way ANOVA, two-way repeated measures ANOVA, and Benjamini–Krieger–Yekutieli correction; the paper states P < 0.5 was considered statistically significant and q < 0.1 for multiple-comparison correction. TEM mitochondrial density/area used four old GFP and four old Parkin white gastrocnemius samples.
Limitations
- The paper does not include a dedicated limitations section. Evident limitations include the use of only male C57BL/6J mice, with no female or human data, so translational relevance is not established.
- The authors state that mechanisms underlying several effects were not investigated, including protection against oxidative stress, increases in mitochondrial biogenesis, and the anti-fibrotic effect.
- The study uses AAV-mediated Parkin overexpression rather than a pharmacological or non-pharmacological intervention, and long-term feasibility or safety of increasing Parkin is not assessed; some analyses relied on small samples, such as TEM with four old GFP and four old Parkin muscles.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
22 Valid · 0 Not valid · 22 Not checked · 59 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interestingly, skeletal muscles from adult Parkin knockout mice display some ageing‐like features, including contractile dysfunction, impaired mitochondrial energetics and a sensitization of the apoptosis‐regulating mitochondrial permeability transition pore (Gouspillou et al. 2018).”
What the sources say
- Supportedcites Gouspillou et al. 2018 source
The Discussion says muscles from Park2−/− mice have depressed contractility and recapitulate mitochondrial features seen in aged skeletal muscle, specifically impaired energetics and a sensitized mitochondrial permeability transition pore. The Results report mild contractile dysfunction, and the Animals section identifies the mice as 8–12 weeks old. Page numbers are unavailable in our copy. (LLM, conf=0.94)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the old group, Parkin overexpression was initiated at 18 months of age because muscle atrophy is not yet detectable at that time point (Hwee et al. 2014).”
What the sources say
- Supportedcites Hwee et al. 2014 source
The Results section reports that muscle mass and fiber cross-sectional area were similar in wild-type and MuRF1 knockout mice through 18 months, while significant muscle atrophy appeared in wild-type mice at 24 months. This supports the cited timing for the mice studied. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Notably, aged skeletal muscles display impaired mitochondrial energetics (Trounce et al. 1989; Short et al. 2005; Gouspillou et al. 2010; Lanza et al. 2012; Gouspillou et al. 2014a) and increased mitochondrial‐mediated apoptosis (Selman et al. 2003; Dirks & Leeuwenburgh, 2004; Leeuwenburgh et al. 2005; Chabi et al. 2008; Marzetti et al. 2008; Picard et al. 2010; Picard et al. 2011; Gouspillou et a”
What the sources say
- Not checked — no full text of the sourcecites Trounce et al. 1989 source
- Not checked — no full text of the sourcecites Short et al. 2005 source
- Supportedcites Gouspillou et al. 2010 source
The Discussion reports a clear reduction in the maximal capacity of oxidative phosphorylation in mitochondria from aged rat skeletal muscle (Tables 2 and 3; article pp. 143–151). This supports the broad claim of impaired mitochondrial energetics, although the paper notes that the physiological consequences of reduced maximal capacity are uncertain. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Prolonged activation of apoptosis can even result in the loss of muscle fibres (Dupont‐Versteegden, 2006).”
What the sources say
- Partly supportedcites Dupont‐Versteegden, 2006 sourceExperimental — accuracy not yet measured
The Conclusion links apoptosis to skeletal muscle atrophy, but describes loss of myonuclei and other cells, not loss of whole muscle fibres. The discussion following ROLE OF APOPTOSIS says that eliminating a nucleus does not necessarily destroy the entire muscle cell. Our copy therefore supports a role in atrophy, but not the specific claim that prolonged apoptosis results in fibre loss. (LLM, conf=0.86)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“our findings add to the available literature showing that Parkin can exert anti‐apoptotic effects (Charan et al. 2014).”
What the sources say
- Supportedcites Charan et al. 2014 source
The Discussion (page unavailable) describes parkin’s inhibition of Bax-dependent cell death and its pro-survival effects. This directly supports the claim that parkin can exert anti-apoptotic effects. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
62 more claims · 2 with their cited sources checked
Create a free account to see all 103 claims and every source verdict.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 22
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Parkin overexpression promotes proteostasis and tissue function of aged muscles both in Drosophila and mice [13, 14]”
From Overexpression of pink1 or parkin in indirect flight muscles promotes mitochondrial proteostasis and extends lifespan in Drosophila melanogaster (2019) · cites this paper as [14]
In the citing paper
“Parkin overexpression not only reduces aging-related increases in markers of oxidative stress, fibrosis, and apoptosis, but also enhances mitochondrial content and enzymatic activities, mitigating sarcopenia and improving skeletal muscle performance [37].”
From Exerkines and Sarcopenia: Unveiling the Mechanism Behind Exercise-Induced Mitochondrial Homeostasis (2025) · cites this paper as [37]
In the citing paper
“In line, overexpression of Parkin attenuates aging-related loss of muscle mass and strength, along with improved mitochondrial biogenesis and enzymatic activities (95).”
From From mitochondria to sarcopenia: role of 17β-estradiol and testosterone (2023) · cites this paper as [95]
In the citing paper
“In line, overexpression of Parkin attenuates aging-related loss of muscle mass and strength, along with improved mitochondrial biogenesis and enzymatic activities (95).”
From From mitochondria to sarcopenia: role of 17β-estradiol and testosterone (2023) · cites this paper as [95]
In the citing paper
“As discussed above, we have shown that overexpressing Parkin in aged skeletal muscles attenuates sarcopenia [152].”
From Mitochondrial Dynamics and Mitophagy in Skeletal Muscle Health and Aging (2021) · cites this paper as [152]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Parkin is recruited selectively to impaired mitochondria and promotes their autophagy
Narendra, D., Tanaka, A., Suen, D.-F., & Youle, R. J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200809125 · Cited by 4,026 · cited 1×
“This process is regulated to a large extent by the Parkin–Pink1 pathway, which plays an important role in maintaining mitochondrial quality in skeletal muscles by selectively removing dysfunctional and depolarized mitochondria (Narendra et al. 2008).”
BackgroundAdaptive linear step-up procedures that control the false discovery rate
Benjamini, Y., Krieger, A. M., & Yekutieli, D. (2006) · Biometrika · doi:10.1093/biomet/93.3.491 · Cited by 3,228
Janssen, I., Heymsfield, S. B., & Ross, R. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50216.x · Cited by 3,139 · cited 1×
“Sarcopenia can have dramatic consequences for afflicted individuals because it progressively leads to mobility impairment, falls and physical frailty (Janssen et al. 2002; Deschenes, 2004; Janssen et al. 2004a; Kim & Choi, 2013).”
BackgroundSkeletal muscle fatigue: cellular mechanisms
Allen, D. G., Lamb, G. D., & Westerblad, H. (2008) · Physiological Reviews · doi:10.1152/physrev.00015.2007 · Cited by 2,495
The healthcare costs of sarcopenia in the United States
Janssen, I., Shepard, D. S., Katzmarzyk, P. T., & Roubenoff, R. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52014.x · Cited by 1,546
Decline in skeletal muscle mitochondrial function with aging in humans
Short, K. R., Bigelow, M. L., Kahl, J., Singh, R., Coenen-Schimke, J., Raghavakaimal, S., & Nair, K. S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501559102 · Cited by 1,333
Autophagy is required to maintain muscle mass.
Masiero, E., Agatea, L., Mammucari, C., Blaauw, B., Loro, E., Komatsu, M., Metzger, D., Reggiani, C., Schiaffino, S., & Sandri, M. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.10.008 · Cited by 1,282
Skeletal Muscle Cutpoints Associated with Elevated Physical Disability Risk in Older Men and Women
Janssen, I. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh058 · Cited by 1,190
Ryu, D., Mouchiroud, L., Andreux, P. A., Katsyuba, E., Moullan, N., Nicolet-dit-Félix, A. A., Williams, E. G., Jha, P., Lo Sasso, G., Huzard, D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4132 · Cited by 1,105
PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
Shin, J.-H., Ko, H. S., Kang, H., Lee, Y., Lee, Y.-I., Pletinkova, O., Troconso, J. C., Dawson, V. L., & Dawson, T. M. (2011) · Cell · doi:10.1016/j.cell.2011.02.010 · Cited by 953
Cited by
The mitophagy pathway and its implications in human diseases
Wang, S., Long, H., Hou, L., Feng, B., Ma, Z., Wu, Y., Zeng, Y., Cai, J., Zhang, D.-W., & Zhao, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01503-7 · Cited by 883
Exercise and mitochondrial health
Memme, J. M., Erlich, A. T., Phukan, G., & Hood, D. A. (2021) · The Journal of Physiology · doi:10.1113/jp278853 · Cited by 343
Crosstalk between mitochondrial biogenesis and mitophagy to maintain mitochondrial homeostasis
Liu, L., Li, Y., Chen, G., & Chen, Q. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00975-7 · Cited by 286
Mitochondrial Dynamics and Mitophagy in Skeletal Muscle Health and Aging
Leduc-Gaudet, J.-P., Hussain, S. N. A., Barreiro, E., & Gouspillou, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158179 · Cited by 268
“Furthermore, in old mice, we found that Parkin over xpression increased muscle strength, increas d mitoch ndrial content, and protected against oxidative stress, fibrosis, and apoptosis [152].”
BackgroundResultInfluentialSelf-citationMitophagy and Oxidative Stress: The Role of Aging
De Gaetano, A., Gibellini, L., Zanini, G., Nasi, M., Cossarizza, A., & Pinti, M. (2021) · Antioxidants · doi:10.3390/antiox10050794 · Cited by 184
Metadata
- Authors
- Leduc‐Gaudet, J., Reynaud, O., Hussain, S. N., & Gouspillou, G.
- Affiliations
- Université du Québec à Montréal (CA)
- McGill University Health Centre (CA)
- Corresponding author
- Gouspillou, Gilles
- Venue
- The Journal of Physiology
- Publisher
- Wiley
- Published
- 2019-01-30
- Volume
- 597
- Issue
- 7
- Pages
- 1975-1991
- ISSN
- 0022-3751 (ISSN-L)
- 1469-7793
- PMC
- PMC6441909
- OpenAlex
- W2911788128
- Cited by
- 119
- References
- 66
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 22 · 2023: 21 · 2022: 16 · 2021: 15 · 2020: 12 · 2019: 11
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Physiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (MOP‐93760)
- Natural Sciences and Engineering Research Council of Canada (RGPIN‐2014‐04668)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- Parkin, sarcopenia, aging, mitophagy, skeletal muscle, muscle hypertrophy, mitochondrial dysfunction, oxidative stress, fibrosis, apoptosis, PGC-1α, adeno-associated virus overexpression, muscle strength, muscle mass, therapeutic target, mitochondrial density, 4-hydroxynonenal, type I collagen, myonuclei, aged mice, mitochondrial enzyme activity
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Aging, Aldehydes, Animals, Male, Mice, Inbred C57BL, Muscle Contraction, Apoptosis, Oxidative Stress, Muscle, Skeletal, Collagen Type I, Ubiquitin-Protein Ligases, Mice, Muscle Strength, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Parkin overexpression protects from ageing‐related loss of muscle mass and strength. https://app.cochat.ai/papers/10.1113/jp277157
- The paper
- Leduc‐Gaudet, J., Reynaud, O., Hussain, S. N., & Gouspillou, G. (2019). Parkin overexpression protects from ageing‐related loss of muscle mass and strength. The Journal of Physiology. https://doi.org/10.1113/jp277157
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.